GNUV204

GNUV204 is a next-generation Interleukin-2 (IL-2) based biologic immunotherapy being developed by Genuv, a clinical-stage biotechnology company based in Seoul. Designed for the treatment of solid tumors, GNUV204 is engineered to overcome the limitations of traditional IL-2 therapies, specifically by minimizing severe side effects such as vascular leak syndrome and regulatory T cell-mediated immune suppression. The program has been recognized and supported by the Korea Drug Development Fund (KDDF), highlighting its potential as a differentiated candidate in the immuno-oncology space that aims to selectively activate effector immune cells for enhanced anti-tumor activity.